180 Life Sciences Corp. announced that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain. As part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), Sir Marc Feldmann’s (the Company’s Co-Executive Chairman and Co-Founder) laboratory, and 180 Life Sciences’ scientists, identified the non-psychoactive CBD analogue as a lead molecule in the Company’s SCA platform. The analog was selected based on a wide-ranging screen of derivatives of cannabidiol and cannabigerol made by Prof Mechoulam. The Company believes that the analog appears to have (1) a novel composition of matter which would enable patent protection, (2) robust preclinical efficacy in several established mouse models for treating pain and inflammation in vivo, and (3) ease of scalability for future good manufacturing practice manufacturing. Its safety profile is being explored in greater detail.